KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Aroxybutynin and atomoxetine (AD109) for obstructive sleep apnea: a randomized phase 3 trial (SynAIRgy).

Patrick J Strollo, Ron Farkas, Luigi Taranto-Montemurro, John Cronin, Sanjay R Patel, SynAIRgy Investigators

Am J Respir Crit Care Med 212(7) 1569-1584

PMID42148495
PMCIDPMC13318230
DOI10.1093/ajrccm/aamag215
发表日期2026-05-18
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 2:非 KM 图;Figure 3:AI 判定为 other。
摘要

摘要

RATIONALE: Many patients with obstructive sleep apnea (OSA) are unable to tolerate long-term positive airway pressure (PAP) therapy, highlighting the need for alternative treatments. AD109 (investigational fixed-dose oral combination of aroxybutynin 2.5 mg/atomoxetine 75 mg) is designed to target neuromuscular dysfunction in OSA. OBJECTIVES: To evaluate the efficacy/safety of AD109 over 6 months in a diverse OSA population unable to use PAP. METHODS: SynAIRgy enrolled adults with mild-to-severe OSA who were intolerant to or refused PAP therapy into a randomized, double-blind, placebo-controlled, 26-week parallel-arm trial of AD109 vs placebo across 69 centers. The primary efficacy endpoint was change from baseline to week 26 in apnea-hypopnea index (AHI). Key secondary endpoints were oxygen desaturation index (ODI), Patient-Reported Outcomes Measurement Information System (PROMIS)-Fatigue T-score, hypoxic burden (HB), PROMIS-Sleep Impairment T-score, and proportion of participants with ≥50% AHI reduction. MEASUREMENTS AND MAIN RESULTS: A total of 646 eligible participants (median age 58 years, 49.3% female, median body mass index 32.4 kg/m2) were randomized. Median baseline AHI was 19.6 events/hour with 35% mild, 42% moderate, and 23% severe OSA. At week 26, mean AHI treatment difference was -4.0 events/hour (95% CI, -6.4 to -1.6; P = .001), representing a model-estimated 44.1% vs 17.6% decrease from baseline (P <.0001). AD109 demonstrated improvements in ODI and HB at week 26 vs placebo; however, no statistically significant difference was observed for PROMIS-Fatigue. Overall, 21.2% of participants on AD109 and 3.1% on placebo discontinued therapy due to adverse events. The most common adverse events with AD109 were dry mouth, nausea, insomnia, and urinary hesitation, with no serious treatment-related adverse events. CONCLUSIONS: AD109 significantly improved airway obstruction and oxygenation at 26 weeks across a broad range of patients unable to use PAP, suggesting that AD109 could become a potential treatment option for patients with OSA. CLINICAL TRIAL REGISTRATION: www.clinicaltrials.gov (NCT05813275 [SynAIRgy]).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Screening, randomization, and follow-up in SynAIRgy participants. *The 7 participants (5 in the AD109 arm and 2 in the placebo arm) randomized and treated in the exploratory cohort are included in the safety analysis but not in the efficacy analyses. † Reason of study discontinuation before receiving study medication was patient decision. ‡ Sixteen participants enrolled at site 1416 in the AD106 arm were excluded from the efficacy analyses because the site was terminated due to Good Clinical Practice noncompliance. § These numbers reflect participants by assigned treatment (2 participants assigned to placebo, received AD109 instead), and the intent-to-treat and on-treatment estimands were performed based on the assigned treatment. ‖ These numbers reflect participants by assigned treatment, but 2 participants who were assigned to placebo received AD109 instead. **Includes 5 participants enrolled and treated in the exploratory cohort and 16 participants enrolled at site 1416. †† These numbers reflect participants by actual treatment and were used for the safety analysis. §§ Six participants enrolled at site 1416 in the placebo arm were excluded from the efficacy analyses because the site was terminated due to Good Clinical Practice noncompliance. ‖‖ Includes 2 participants enrolled and treated in the exploratory cohort and 6 participants enrolled at site 1416.
非 KM Figure
Figure 2Reductions in AHI with AD109 as compared with placebo at weeks 4 and 26 and disease severity classification at week 26 (primary and exploratory endpoints). Model-generated geometric mean percent reduction in AHI from baseline to weeks 4 and 26 for the ITT (A) and on-treatment estimands (D). Observed median AHI at baseline to weeks 4 and 26 for the ITT (B) and on-treatment estimand (E). Proportion of participants with change in OSA severity category from baseline to week 26 in the ITT (C) and on-treatment estimands (F). In (A) and (C), due to skewed distribution, AHI was analyzed and modeled on the natural log scale; least squares mean estimated relative change from baseline from mixed model for repeated measurements analysis were back-transformed to original scale of relative change from baseline and expressed as a percentage for presentation. Log (0.01) was used if AHI was reported as 0. Error bars in (A, B, D, and E) represent 95% CIs. **** P <.0001 vs placebo. Abbreviations: AHI, apnea–hypopnea index based on 4% desaturation; CI, confidence interval; ITT, intent to treat; OSA, obstructive sleep apnea.
非 KM Figure
Figure 3AHI responder analysis with AD109 as compared with placebo (exploratory endpoints). Proportion of participants with AHI reduction of ≥30% to ≥90% at week 26 in the ITT (A) and the on-treatment estimands (B). (A) is a supportive analysis in which missing data were treated as nonresponders; observed data off treatment were included. **** P <.0001 vs placebo. *** P <.001 vs placebo. ** P <.01 vs placebo. Abbreviations: AHI, apnea–hypopnea index based on 4% desaturation; ITT, intent to treat.
非 KM Figure